Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Polycystic Ovary Syndrome 2Skin Diseases 1Sarcoma 1Rare Diseases 1Neoplasms 1Lymphoma 1Hematologic Neoplasms 1Endocrine System Diseases 1Breast Neoplasms 1Advanced Malignant Neoplasm 1Acanthosis Nigricans 1

Interventions

Cyclophosphamide 241Rituximab 223Etoposide 138Filgrastim 113Vincristine 112Doxorubicin 104Prednisone 90Cytarabine 90Methotrexate 79fludarabine phosphate 77Radiotherapy 76Peripheral Blood Stem Cell Transplantation 71Melphalan 71Busulfan 60Tacrolimus 48Dexamethasone 48Mycophenolic Acid 46Carmustine 46Granulocyte Colony-Stimulating Factor 44fludarabine 43Antilymphocyte Serum 40Ifosfamide 38sargramostim 34Whole-Body Irradiation 34Cyclosporine 33Bortezomib 32Gemcitabine 30Methylprednisolone 27Bendamustine Hydrochloride 27Lenalidomide 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma × Spironolactone × Clear all
NCT04190433 2023-05-24

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Mayo Clinic

Phase 2 Withdrawn
BreastLymphoidOther hematologic neoplasmSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡